These data were supported by various studies demonstrating an overexpression of apelin and its receptor at the protein level in glioblastoma, oral cancer, colon adenocarcinoma and non-small-cell lung cancer [22,23,24,25]. This evidence concerns the gene APLN and colon adenocarcinoma.